ArticleBreast cancer research : BCR2026
A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers.
Article in Breast cancer research : BCR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBreast cancer (BC) is the most common cancer in women and the leading cause of cancer-related death worldwide. Systemic immune dysregulation is increasingly recognized as a critical component of BC pathophysiology. Therefore, the characterization of inflammatory mediators in this neoplasia has emerged as a focus of increasing research.
methodsIn this study, we performed a multiplex analysis of 62 circulating immune-related molecules in serum samples from 229 BC patients prior to any treatment and 50 healthy controls. Serum samples were analyzed using the LEGENDplex™ protocol and measured by a spectral flow cytometer.
resultsAmong the 62 circulating immune-related molecules initially analyzed, we identified a distinct serum signature comprising 27 soluble factors that significantly discriminated BC patients from healthy controls. The integration of these biomarkers into supervised machine learning models revealed that the Light Gradient Boosting Machine (LightGBM) algorithm achieved optimal diagnostic performance (AUC = 0.91; accuracy = 96.4%), with TSLP, IL-8, and IL-1β emerging as key predictive features. By integrating clinicopathological data, we identified significant associations between immune factor levels and tumor characteristics, including proliferation, lymph-node involvement, and histological grade. Stratification by molecular subtype also revealed distinct immunologic patterns. Significantly, elevated levels of IL-2RA and PD-1 were identified as promising candidates to predict shorter overall and disease-free survival, respectively.
conclusionThese findings provide novel insights into the systemic immune landscape of early-stage BC and support the use of circulating immune mediators as minimally invasive biomarkers for diagnosis and prognosis. However, external validation is needed to confirm the robustness and generalizability of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.